Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Positive 92.0%

Neg 0% Neu 0% Pos 92%

Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.